(2022) Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review
The results were positive, with significant reductions in multiple risk markers related to heart disease and type 2 diabetes [9]
GLP-1 (glucagon-like peptide-1) medications were originally developed to treat type 2 diabetes, but theyve made headlines for their ability to support weight loss even in people without diabetes
Within the past two years, GLP-1 agonists, such as semaglutide and tirzepatide, have emerged as effective treatments in the fight against obesity and weight loss resistance
Inconsistent injection schedules or missed doses prevent steady-state blood levels, allowing hunger signals to resurface between doses
Wegovy And then theres Wegovy , the third semaglutide-based medication to hit the market